pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
Sep 24, 26
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
Sep 23, 26
Berlin Seeds Recalls Alfalfa Sprouting Seed Because of Possible Health Risk
fda recalls
Sep 23, 26
Enveda, an AI drugmaker, banks $311M in venture funding
biopharma dive
Sep 23, 26
Roche, Ionis RNA drug scores in kidney disease study
biopharma dive
Sep 23, 26
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
Sep 23, 26
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
biospace
Sep 23, 26
Roivant reports Phase 2b lupus failure for an FcRn drug
endpoints
Sep 23, 26
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study
biospace
Sep 23, 26
Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures
fiercebiotech
Sep 23, 26
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
fiercebiotech
Sep 22, 26
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
Sep 22, 26
Opinion: Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA
stat
Sep 22, 26
Celldex sinks as safety concerns cloud immune drug results
biopharma dive
Sep 22, 26
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
Sep 22, 26
2026 IPO blitz continues with 4 new biotech filings
biospace
Sep 22, 26
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
Sep 22, 26
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
Sep 22, 26
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
fiercebiotech
Sep 22, 26
Opinion: The science on relieving cancer symptoms is clear. Why isn’t insurance paying?
stat
Sep 21, 26
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
fiercebiotech
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 21, 26
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
endpoints
Sep 21, 26
Skeptical about modern medicine? I know the feeling — and want to listen
stat
Sep 21, 26
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
Sep 21, 26
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
Sep 20, 26
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
Sep 18, 26
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
Sep 18, 26
Electra lights up with $350M IPO for pivotal immune-disease drug development
biospace
Sep 18, 26
STAT+: Roche expands its Boston footprint with new research center
stat
Sep 18, 26
Inflammation biotech Electra charges up with $350M from upsized IPO
fiercebiotech
← prev
page 14 of 34
next →